Clinical Stage III Cutaneous Melanoma AJCC v8

Oncology·MeSH: Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

5 drugs in development·3 companies·7 clinical trials

Drug Pipeline by Phase

Compare drugs

Cabozantinib S-malate vs LHRH AgonistCabozantinib S-malate vs VLP-encapsulated TLR9 Agonist CMP-001Cabozantinib S-malate vs SST3 Agonist Program

Frequently asked questions

How many drugs are in development for Clinical Stage III Cutaneous Melanoma AJCC v8?

BioSniper tracks 5 drugs in development for Clinical Stage III Cutaneous Melanoma AJCC v8 across 3 companies.

How many clinical trials target Clinical Stage III Cutaneous Melanoma AJCC v8?

There are 7 clinical trials targeting Clinical Stage III Cutaneous Melanoma AJCC v8 tracked by BioSniper.

What is the prevalence of Clinical Stage III Cutaneous Melanoma AJCC v8?

The estimated prevalence of Clinical Stage III Cutaneous Melanoma AJCC v8 is approximately 75.0 per 100,000 population.

Deep-dive into Clinical Stage III Cutaneous Melanoma AJCC v8

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Clinical Stage III Cutaneous Melanoma AJCC v8 — Drugs in Development & Clinical Trials | BioSniper